Copyright Reports & Markets. All rights reserved.

Global Oral hypoglycemic agents and insulin analogues Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Oral hypoglycemic agents and insulin analogues Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Oral hypoglycemic agents and insulin analogues Market Size Growth Rate by Product
      • 1.4.2 Insulin Secretagogues
      • 1.4.3 Alpha-glucosidase Inhibitors
      • 1.4.4 Insulin Sensitizers
    • 1.5 Market by End User
      • 1.5.1 Global Oral hypoglycemic agents and insulin analogues Market Size Growth Rate by End User
      • 1.5.2 Hospitals
      • 1.5.3 Drug Store
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Oral hypoglycemic agents and insulin analogues Market Size
      • 2.1.1 Global Oral hypoglycemic agents and insulin analogues Revenue 2014-2025
      • 2.1.2 Global Oral hypoglycemic agents and insulin analogues Sales 2014-2025
    • 2.2 Oral hypoglycemic agents and insulin analogues Growth Rate by Regions
      • 2.2.1 Global Oral hypoglycemic agents and insulin analogues Sales by Regions
      • 2.2.2 Global Oral hypoglycemic agents and insulin analogues Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Oral hypoglycemic agents and insulin analogues Sales by Manufacturers
      • 3.1.1 Oral hypoglycemic agents and insulin analogues Sales by Manufacturers
      • 3.1.2 Oral hypoglycemic agents and insulin analogues Sales Market Share by Manufacturers
      • 3.1.3 Global Oral hypoglycemic agents and insulin analogues Market Concentration Ratio (CR5 and HHI)
    • 3.2 Oral hypoglycemic agents and insulin analogues Revenue by Manufacturers
      • 3.2.1 Oral hypoglycemic agents and insulin analogues Revenue by Manufacturers (2014-2019)
      • 3.2.2 Oral hypoglycemic agents and insulin analogues Revenue Share by Manufacturers (2014-2019)
    • 3.3 Oral hypoglycemic agents and insulin analogues Price by Manufacturers
    • 3.4 Oral hypoglycemic agents and insulin analogues Manufacturing Base Distribution, Product Types
      • 3.4.1 Oral hypoglycemic agents and insulin analogues Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Oral hypoglycemic agents and insulin analogues Product Type
      • 3.4.3 Date of International Manufacturers Enter into Oral hypoglycemic agents and insulin analogues Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Oral hypoglycemic agents and insulin analogues Sales by Product
    • 4.2 Global Oral hypoglycemic agents and insulin analogues Revenue by Product
    • 4.3 Oral hypoglycemic agents and insulin analogues Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Oral hypoglycemic agents and insulin analogues Breakdown Data by End User

    6 North America

    • 6.1 North America Oral hypoglycemic agents and insulin analogues by Countries
      • 6.1.1 North America Oral hypoglycemic agents and insulin analogues Sales by Countries
      • 6.1.2 North America Oral hypoglycemic agents and insulin analogues Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Oral hypoglycemic agents and insulin analogues by Product
    • 6.3 North America Oral hypoglycemic agents and insulin analogues by End User

    7 Europe

    • 7.1 Europe Oral hypoglycemic agents and insulin analogues by Countries
      • 7.1.1 Europe Oral hypoglycemic agents and insulin analogues Sales by Countries
      • 7.1.2 Europe Oral hypoglycemic agents and insulin analogues Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Oral hypoglycemic agents and insulin analogues by Product
    • 7.3 Europe Oral hypoglycemic agents and insulin analogues by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Oral hypoglycemic agents and insulin analogues by Countries
      • 8.1.1 Asia Pacific Oral hypoglycemic agents and insulin analogues Sales by Countries
      • 8.1.2 Asia Pacific Oral hypoglycemic agents and insulin analogues Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Oral hypoglycemic agents and insulin analogues by Product
    • 8.3 Asia Pacific Oral hypoglycemic agents and insulin analogues by End User

    9 Central & South America

    • 9.1 Central & South America Oral hypoglycemic agents and insulin analogues by Countries
      • 9.1.1 Central & South America Oral hypoglycemic agents and insulin analogues Sales by Countries
      • 9.1.2 Central & South America Oral hypoglycemic agents and insulin analogues Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Oral hypoglycemic agents and insulin analogues by Product
    • 9.3 Central & South America Oral hypoglycemic agents and insulin analogues by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Oral hypoglycemic agents and insulin analogues by Countries
      • 10.1.1 Middle East and Africa Oral hypoglycemic agents and insulin analogues Sales by Countries
      • 10.1.2 Middle East and Africa Oral hypoglycemic agents and insulin analogues Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Oral hypoglycemic agents and insulin analogues by Product
    • 10.3 Middle East and Africa Oral hypoglycemic agents and insulin analogues by End User

    11 Company Profiles

    • 11.1 Sanofi-Aventis
      • 11.1.1 Sanofi-Aventis Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Sanofi-Aventis Oral hypoglycemic agents and insulin analogues Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Sanofi-Aventis Oral hypoglycemic agents and insulin analogues Products Offered
      • 11.1.5 Sanofi-Aventis Recent Development
    • 11.2 Ganlee
      • 11.2.1 Ganlee Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Ganlee Oral hypoglycemic agents and insulin analogues Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Ganlee Oral hypoglycemic agents and insulin analogues Products Offered
      • 11.2.5 Ganlee Recent Development
    • 11.3 Biocon
      • 11.3.1 Biocon Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Biocon Oral hypoglycemic agents and insulin analogues Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Biocon Oral hypoglycemic agents and insulin analogues Products Offered
      • 11.3.5 Biocon Recent Development
    • 11.4 Novo Nordisk
      • 11.4.1 Novo Nordisk Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Novo Nordisk Oral hypoglycemic agents and insulin analogues Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Novo Nordisk Oral hypoglycemic agents and insulin analogues Products Offered
      • 11.4.5 Novo Nordisk Recent Development
    • 11.5 Eli Lilly
      • 11.5.1 Eli Lilly Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Eli Lilly Oral hypoglycemic agents and insulin analogues Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Eli Lilly Oral hypoglycemic agents and insulin analogues Products Offered
      • 11.5.5 Eli Lilly Recent Development
    • 11.6 Tonghua Dongbao
      • 11.6.1 Tonghua Dongbao Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Tonghua Dongbao Oral hypoglycemic agents and insulin analogues Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Tonghua Dongbao Oral hypoglycemic agents and insulin analogues Products Offered
      • 11.6.5 Tonghua Dongbao Recent Development
    • 11.7 United Laboratory
      • 11.7.1 United Laboratory Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 United Laboratory Oral hypoglycemic agents and insulin analogues Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 United Laboratory Oral hypoglycemic agents and insulin analogues Products Offered
      • 11.7.5 United Laboratory Recent Development
    • 11.8 Jiangsu Wanbang
      • 11.8.1 Jiangsu Wanbang Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Jiangsu Wanbang Oral hypoglycemic agents and insulin analogues Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Jiangsu Wanbang Oral hypoglycemic agents and insulin analogues Products Offered
      • 11.8.5 Jiangsu Wanbang Recent Development

    12 Future Forecast

    • 12.1 Oral hypoglycemic agents and insulin analogues Market Forecast by Regions
      • 12.1.1 Global Oral hypoglycemic agents and insulin analogues Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Oral hypoglycemic agents and insulin analogues Revenue Forecast by Regions 2019-2025
    • 12.2 Oral hypoglycemic agents and insulin analogues Market Forecast by Product
      • 12.2.1 Global Oral hypoglycemic agents and insulin analogues Sales Forecast by Product 2019-2025
      • 12.2.2 Global Oral hypoglycemic agents and insulin analogues Revenue Forecast by Product 2019-2025
    • 12.3 Oral hypoglycemic agents and insulin analogues Market Forecast by End User
    • 12.4 North America Oral hypoglycemic agents and insulin analogues Forecast
    • 12.5 Europe Oral hypoglycemic agents and insulin analogues Forecast
    • 12.6 Asia Pacific Oral hypoglycemic agents and insulin analogues Forecast
    • 12.7 Central & South America Oral hypoglycemic agents and insulin analogues Forecast
    • 12.8 Middle East and Africa Oral hypoglycemic agents and insulin analogues Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Oral hypoglycemic agents and insulin analogues Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Oral hypoglycemic agents and insulin analogues market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Oral hypoglycemic agents and insulin analogues market based on company, product type, end user and key regions.

      This report studies the global market size of Oral hypoglycemic agents and insulin analogues in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Oral hypoglycemic agents and insulin analogues in these regions.
      This research report categorizes the global Oral hypoglycemic agents and insulin analogues market by top players/brands, region, type and end user. This report also studies the global Oral hypoglycemic agents and insulin analogues market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Sanofi-Aventis
      Ganlee
      Biocon
      Novo Nordisk
      Eli Lilly
      Tonghua Dongbao
      United Laboratory
      Jiangsu Wanbang

      Market size by Product
      Insulin Secretagogues
      Alpha-glucosidase Inhibitors
      Insulin Sensitizers
      Market size by End User
      Hospitals
      Drug Store
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Oral hypoglycemic agents and insulin analogues market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Oral hypoglycemic agents and insulin analogues market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Oral hypoglycemic agents and insulin analogues companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Oral hypoglycemic agents and insulin analogues submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Oral hypoglycemic agents and insulin analogues are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Oral hypoglycemic agents and insulin analogues market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now